Database for
Therapeutic Antibodies
Therapeutic Antibodies
| Entry ID | 350 |
| INN | Rilvegostomig |
| Status | Clinical |
| Drug code(s) | AZD2936 |
| Brand name | None |
| mAb sequence source | mAb humanized |
| General Molecular Category | Bispecific |
| Format, general category | Full length Ab |
| Format details | None |
| Isotype (Fc) | IgG1 |
| Light chain isotype | kappa/lambda |
| Linker | None |
| Ave. DAR | None |
| Conjugated/fused moiety | None |
| Discovery method/technology | None |
| Target(s) | PD-1, TIGIT |
| Indications of clinical studies | Biliary tract cancer, Non-small cell lung cancer |
| Primary therapeutic area | Cancer |
| Most advanced stage of development (global) | Phase 3 |
| Status | Active |
| Start of clinical phase (IND filing or first Phase 1) | October 01, 2021 |
| Start of Phase 2 | September 14, 2022 |
| Start of Phase 3 | |
| Date BLA/NDA submitted to FDA | |
| Year of first approval (global) | None |
| Date of first US approval | |
| INN, US product name | None |
| US or EU approved indications | None |
| Company | AstraZeneca |
| Licensee/Partner | Compugen Ltd. |
| Comments about company or candidate | Phase 3 studies for Biliary tract cancer (NCT06109779, NCT06467357), Non-Small Cell Lung Cancer (NCT06357533, NCT06564844) are recruiting as of December 3, 2024; and for Non-Small Cell Lung Cancer (NCT06692738) and Non-squamous Non-Small Cell Lung Cancer (NCT06627647) are not yet recruiting as of December 3, 2024. NCT06627647 and NCT06692738 Phase 3 in NSCLC due to start in Nov 2024 NCT06109779 Phase 3 study in biliary tract cancer started in Dec 2023. Feb 2023: Phase 3 study with rilvegostomig, AstraZeneca's PD-1/TIGIT bi-specific derived from Compugen's COM902 is expected to start in 2023. NCT05702229 Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma started in Jan 2023. Nov. 16, 2022: Compugen Ltd. announced today that it expects to receive a milestone payment of $7.5 million from AstraZeneca, after AstraZeneca dosed the first patient in its ARTEMIDE Phase 1/2 study with AZD2936 (NCT04995523) in NSCLC. October 4, 2021 I Compugen Ltd. announced that Compugen is entitled to receive a $6 million milestone payment from AstraZeneca triggered by the dosing of the first patient in a Phase 1/2 study evaluating AZD2936, a TIGIT/PD-1 bispecific antibody, in patients with advanced or metastatic non-small cell lung cancer. AZD2936 is derived from COM902, Compugen's high-affinity clinical-stage anti-TIGIT antibody. |
| Full address of company | Cambridge, United Kingdom Europe United Kingdom https://www.astrazeneca.com/our-company/contact-us.html |
Rilvegostomig was engineered to reduce Fc effector functionality.
| Anticipated events | None |
| Factor(s) contributing to discontinuation | None |